The DPYSL4 antibody is a tool used to detect the dihydropyrimidinase-like protein 4 (DPYSL4), a member of the collapsin response mediator protein (CRMP) family. DPYSL4. also known as CRMP-3 or ULIP6. is a cytosolic phosphoprotein primarily expressed in the nervous system. It plays critical roles in neuronal development, including axon guidance, growth cone collapse, and neuronal migration, by regulating microtubule dynamics and cytoskeletal organization. Structurally, DPYSL4 contains an N-terminal dihydropyrimidinase-like domain and a C-terminal α-helical region, with its activity modulated by phosphorylation.
Research has linked DPYSL4 to neurological disorders, such as Alzheimer's disease and schizophrenia, where altered expression or dysfunction may contribute to synaptic deficits. Additionally, DPYSL4 is implicated in cancer, with studies suggesting its involvement in tumor metastasis, invasion, and chemoresistance in various malignancies. The DPYSL4 antibody is widely utilized in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression levels, cellular localization, and post-translational modifications.
Commercial DPYSL4 antibodies are typically raised in rabbits or mice using recombinant protein fragments or synthetic peptides. Validation includes specificity testing via knockout controls and functional assays. Its applications span basic neuroscience, cancer biology, and drug discovery, making it a valuable reagent for understanding DPYSL4's physiological and pathological roles.